Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1973 1
1990 1
1992 1
2000 1
2013 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Scleroderma: nomenclature, etiology, pathogenesis, prognosis, and treatments: facts and controversies.
Fett N. Fett N. Clin Dermatol. 2013 Jul-Aug;31(4):432-437. doi: 10.1016/j.clindermatol.2013.01.010. Clin Dermatol. 2013. PMID: 23806160 Review.
The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemic sclerosis, diffuse cutaneous systemic sclerosis, and systemic sclerosis sine scleroderma encompassing the currently acce …
The nomenclature of scleroderma has changed dramatically in recent years, with morphea (localized scleroderma), limited cutaneous systemi …
Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis.
Morita A, Kobayashi K, Isomura I, Tsuji T, Krutmann J. Morita A, et al. J Am Acad Dermatol. 2000 Oct;43(4):670-4. doi: 10.1067/mjd.2000.105165. J Am Acad Dermatol. 2000. PMID: 11004624 Clinical Trial.
OBJECTIVE: Our purpose was to determine whether UVA1 phototherapy is effective for systemic sclerosis. METHODS: Lesional skin on the forearms of patients with systemic sclerosis (diffuse type, n =3; limited type, n =1) was exposed to medium-dose UVA1 radiatio …
OBJECTIVE: Our purpose was to determine whether UVA1 phototherapy is effective for systemic sclerosis. METHODS: Lesional skin on the forearm …
Penicillamine in systemic sclerosis: a reappraisal.
Sattar MA, Guindi RT, Sugathan TN. Sattar MA, et al. Clin Rheumatol. 1990 Dec;9(4):517-22. doi: 10.1007/BF02030514. Clin Rheumatol. 1990. PMID: 2088649
In a 36-month prospective trial 21 patients with systemic sclerosis (diffuse systemic sclerosis 16 patients and 5 subjects with limited cutaneous subtype) were treated with D-penicillamine. ...
In a 36-month prospective trial 21 patients with systemic sclerosis (diffuse systemic sclerosis 16 patients and …
Hemolytic uremic syndrome in a patient with systemic sclerosis treated with cyclosporin A.
Zachariae H, Hansen HE, Olsen TS. Zachariae H, et al. Acta Derm Venereol. 1992 Aug;72(4):307-9. Acta Derm Venereol. 1992. PMID: 1357898
The case is presented of a 48-year-old female suffering from diffuse cutaneous systemic sclerosis (diffuse scleroderma) since 8 years, who went into renal failure as part of hemolytic uremic syndrome following 3 weeks' treatment with 3.8 mg/kg cyclosporin A. …
The case is presented of a 48-year-old female suffering from diffuse cutaneous systemic sclerosis (diffuse scleroderma) …